Progress in neuro-psychopharmacology & biological psychiatry
October 3, 2017
Mohini Ranganathan, Rajiv Radhakrishnan, Peter H Addy et al.
Cannabis and agonists of the brain cannabinoid receptor (CB1R) produce acute memory impairments in humans. However, the extent to which cannabinoids impair the component processes of encoding and retrieval has not been established in humans. The objective of this analysis was to determine whether the administration of Δ9-Tetrahydrocannabinol (THC), the principal psychoactive constituent of...
Psychopharmacology
June 2014
Mohini Ranganathan, R Andrew Sewell, Michelle Carbuto et al.
A family history (FH) of alcoholism accounts for approximately 50% of the risk of developing alcohol problems. Several lines of preclinical evidence suggest that brain cannabinoid receptor (CB1R) function may mediate the effects of alcohol and risk for developing alcoholism including the observations that reduced CB1R function decreases alcohol-related behaviors and enhanced CB1R function...
Psychopharmacology
November 24, 2012
R. A. Sewell, Ashley Schnakenberg, Jacqueline Elander et al.
Cannabinoids have been shown to alter time perception, but existing literature has several limitations. Few studies have included both time estimation and production tasks, few control for subvocal counting, most had small sample sizes, some did not record subjects’ cannabis use, many tested only one dose, and used either oral or inhaled administration of Δ9-tetrahydrocannabinol (THC), leading...
Psychopharmacology
February 2012
Michelle Carbuto, R Andrew Sewell, Ashley Williams et al.
Delta-9-tetrahydrocannabinol (THC) is one of the few cannabinoid receptor ligands that can be used to probe the cannabinoid system in humans. Despite increasing interest in the cannabinoid receptor system, use of intravenous THC as a research tool has been limited by concerns about its abuse liability and psychoactive effects. This study aims to evaluate the safety of all intravenous THC...